UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Totality of Evidence of the effectiveness of repurposed therapies for COVID-19: Can we use Real-World Studies alongside Randomised Controlled Trials?

Clinical and translational science, 2023-10, Vol.16 (10), p.1842-1855

2023

Volltextzugriff (PDF)

Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches

Therapeutic innovation & regulatory science, 2021-07, Vol.55 (4), p.866-871

2021

Volltextzugriff (PDF)

Open Science to Address COVID-19: Sharing Data to Make Our Research Investment Go Further

Therapeutic innovation & regulatory science, 2021-05, Vol.55 (3), p.558-560

2021

Volltextzugriff (PDF)

Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics

Contemporary clinical trials, 2023-09, Vol.132, p.107292-107292, Article 107292

2023

Volltextzugriff (PDF)

Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics

Statistics in biopharmaceutical research, 2022-01, Vol.14 (1), p.5-21

2022

Volltextzugriff (PDF)

Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products

European journal of clinical pharmacology, 2001-11, Vol.57 (9), p.663-670

2001

Volltextzugriff (PDF)

Population and Individual Bioequivalence: Lessons from Real Data and Simulation Studies

Journal of clinical pharmacology, 2001-08, Vol.41 (8), p.811-822

2001

Volltextzugriff (PDF)

Case studies, practical issues and observations on population and individual bioequivalence

Statistics in medicine, 2000-10, Vol.19 (20), p.2811-2820

2000

Volltextzugriff (PDF)

Health data poverty: an assailable barrier to equitable digital health care

The Lancet. Digital health, 2021-04, Vol.3 (4), p.e260-e265

2021

Volltextzugriff (PDF)

Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults

American journal of health-system pharmacy, 1997-05, Vol.54 (10), p.1172-1176

1997

Volltextzugriff (PDF)

Modeling and Interpreting QTc Prolongation in Clinical Pharmacology Studies

Drug information journal, 2005-10, Vol.39 (4), p.437-445

2005

Volltextzugriff (PDF)

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

The Lancet (British edition), 2010-05, Vol.375 (9725), p.1536-1544

2010

Volltextzugriff (PDF)

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

The Lancet (British edition), 2010-05, Vol.375 (9725), p.1536-1544

2010

Volltextzugriff (PDF)

Data capture and sharing in the COVID-19 pandemic: a cause for concern

The Lancet. Digital health, 2022-10, Vol.4 (10), p.e748-e756

2022

Volltextzugriff (PDF)

Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3030-3030

2023

Volltextzugriff (PDF)

Streamlining cardiovascular clinical trials to improve efficiency and generalisability

Heart (British Cardiac Society), 2017-08, Vol.103 (15), p.1156-1162

2017

Volltextzugriff (PDF)

The ABC of pharmaceutical trial design: some basic principles

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2002-06, Vol.1 (1), p.45-53

2002

Volltextzugriff (PDF)

PhRMA Perspective on Population and Individual Bioequivalence

Journal of clinical pharmacology, 2000-06, Vol.40 (6), p.561-570

2000

Volltextzugriff (PDF)

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food

Biopharmaceutics & drug disposition, 1998-09, Vol.19 (6), p.351-356

1998

Volltextzugriff (PDF)

Pharmacokinetics and Protein Binding of Eprosartan in Healthy Volunteers and in Patients with Varying Degrees of Renal Impairment

Journal of clinical pharmacology, 1998-02, Vol.38 (2), p.129-137

1998

Volltextzugriff (PDF)

Comparative Effects of Nabumetone, Sulindac, and Indomethacin on Urinary Prostaglandin Excretion and Platelet Function in Volunteers

Journal of clinical pharmacology, 1994-11, Vol.34 (11), p.1098-1108

1994

Volltextzugriff (PDF)

Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team

Drug information journal, 2005-07, Vol.39 (3), p.243-265

Patterson, Scott D.

2005

Volltextzugriff (PDF)

A dose‐response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1‐receptor antagonist, in sodium‐replete healthy men

Clinical pharmacology and therapeutics, 1998-04, Vol.63 (4), p.471-481

1998

Volltextzugriff (PDF)

Effect of age and gender on the pharmacokinetics of eprosartan

British journal of clinical pharmacology, 1998-09, Vol.46 (3), p.267-270

1998

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(34)
Buchkapitel
(1)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Totality of Evidence of the effectiveness of repurposed therapies for COVID-19: Can we use Real-World Studies alongside Randomised Controlled Trials?

Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches

Open Science to Address COVID-19: Sharing Data to Make Our Research Investment Go Further

Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics

Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products

Population and Individual Bioequivalence: Lessons from Real Data and Simulation Studies

Case studies, practical issues and observations on population and individual bioequivalence

Health data poverty: an assailable barrier to equitable digital health care

Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults

Modeling and Interpreting QTc Prolongation in Clinical Pharmacology Studies

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

Data capture and sharing in the COVID-19 pandemic: a cause for concern

Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials

Streamlining cardiovascular clinical trials to improve efficiency and generalisability

The ABC of pharmaceutical trial design: some basic principles

PhRMA Perspective on Population and Individual Bioequivalence

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food

Pharmacokinetics and Protein Binding of Eprosartan in Healthy Volunteers and in Patients with Varying Degrees of Renal Impairment

Comparative Effects of Nabumetone, Sulindac, and Indomethacin on Urinary Prostaglandin Excretion and Platelet Function in Volunteers

Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team

A dose‐response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1‐receptor antagonist, in sodium‐replete healthy men

Effect of age and gender on the pharmacokinetics of eprosartan

Suchergebnisse filtern